We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Distinctive mRNA Signatures May Prove Diagnostic for Cancer-Related AIS

By LabMedica International staff writers
Posted on 22 Sep 2019
Print article
Image: A micrograph of the superficial cerebral cortex showing neuron loss and reactive astrocytes in a person who has had a stroke (Photo courtesy of Wikimedia Commons).
Image: A micrograph of the superficial cerebral cortex showing neuron loss and reactive astrocytes in a person who has had a stroke (Photo courtesy of Wikimedia Commons).
A recently published paper described a distinctive molecular signature present in blood mRNA expression profiles of patients with cancer-related acute ischemic stroke (AIS) that could potentially lead to earlier diagnosis of cancer in these patients.

Cancer is commonly diagnosed in patients with AIS. Since blood mRNA profiles can distinguish AIS mechanisms, a team of cancer investigators from several institutions including Weill Cornell Medical College (New York, NY, USA) and the University of California, Davis (USA) hypothesized that cancer-related AIS would have a distinctive gene expression profile.

To test this theory, the investigators evaluated four groups of 10 subjects prospectively enrolled at three centers from 2009 to 2018. This population included the group of interest with active solid tumor cancer and AIS and three control groups with active cancer only, AIS only, or vascular risk factors only. Subjects in the AIS-only and cancer-only groups were matched to subjects in the cancer-stroke group by age, sex, and cancer type (if applicable). Subjects in the vascular risk factor group were matched to subjects in the cancer-stroke and stroke-only groups by age, sex, and vascular risk factors. Blood was drawn 72 to 120 hours after stroke, and total RNA was analyzed using 3′ mRNA sequencing.

Results revealed that more than half of strokes in the cancer-stroke group were not caused by traditional risk factors. In total, more than 12,000 genes were analyzed and comparing the cancer-stroke group to the stroke-only group and after accounting for cancer-only genes, 438 genes were found to be differentially expressed. These genes were linked to upregulation of multiple genes/pathways implicated in autophagy signaling, immunity/inflammation, and gene regulation, including interleukin-1, interferon, relaxin, mammalian target of rapamycin signaling, SQSTMI1 (sequestosome-1), and CREB1 (cAMP response element binding protein-1).

"We clearly see that cancer-stroke patients have a unique gene expression profile," said first author Dr Babak Navi, chief of stroke and hospital neurology at Weill Cornell Medical College. "No one before had differentiated gene expression between patients with cancer, stroke, or both. A blood test would be easier, safer, and less expensive than a CT or PET scan to diagnose cancer."

The report was published in the September 12, 2019, online edition of the journal Stroke.

Related Links:
Weill Cornell Medical College
University of California, Davis

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Microbiology

view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more

Pathology

view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.